KASL clinical practice guidelines for management of autoimmune hepatitis 2022

키워드

참고문헌 (369)

1. Guyatt G, "GRADE guidelines : 1. Introduction-GRADE evidence profiles and summary of findings tables", J Clin Epidemiol, 64, pp.383~394 (2011)
2. Balshem H, "GRADE guidelines : 3. Rating the quality of evidence", J Clin Epidemiol, 64, pp.401~406 (2011)
3. "GRADE Handbook"[URL]
4. Andrews J, "GRADE guidelines : 14. Going from evidence to recommendations : the significance and presentation of recommendations", J Clin Epidemiol, 66, pp.719~725 (2013)
5. Lv T, "Systematic review and meta-analysis on the incidence and prevalence of autoimmune hepatitis in Asian, European, and American population", J Gastroenterol Hepatol, 34, pp.1676~1684 (2019)
6. Kim BH, "Populationbased prevalence, incidence, and disease burden of autoimmune hepatitis in South Korea", PLoS One, 12, pp.e0182391~ (2017)
7. Grønbæk L, "Autoimmune hepatitis in Denmark : incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study", J Hepatol, 60, pp.612~617 (2014)
8. Danielsson Borssén Å, "Epidemiology and causes of death in a Swedish cohort of patients with autoimmune hepatitis", Scand J Gastroenterol, 52, pp.1022~1028 (2017)
9. Lamba M, "Trends in incidence of autoimmune liver diseases and increasing incidence of autoimmune hepatitis", Clin Gastroenterol Hepatol, 19, pp.573~579 (2021)
10. Grønbaek L, "Incidence, prevalence and mortality of autoimmune hepatitis in England 1997-2015. A population-based cohort study", Liver Int, 40, pp.1634~1644 (2020)
11. Tunio NA, "Epidemiology of autoimmune hepatitis(AIH)in the United States between 2014 and 2019 : A population-based national study", J Clin Gastroenterol, 55, pp.903~910 (2021)
12. Tanaka A, "Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan", Hepatol Res, 49, pp.881~889 (2019)
13. Czaja AJ, "Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis", Hepatology, 25, pp.317~323 (1997)
14. Vázquez-García MN, "MHC class II sequences of susceptibility and protection in Mexicans with autoimmune hepatitis", J Hepatol, 28, pp.985~990 (1998)
15. Oka S, "HLA-DRB1 and DQB1 alleles in Japanese type 1 autoimmune hepatitis : The predisposing role of the DR4", DR8 heterozygous genotype, 2017, pp.12, e0187325~
16. Lim YS, "Susceptibility to type 1 autoimmune hepatitis is associated with shared amino acid sequences at positions 70-74 of the HLADRB1 molecule", J Hepatol, 48, pp.133~139 (2008)
17. Krawitt EL, "Autoimmune hepatitis", N Engl J Med, 354, pp.54~66 (2006)
18. Wang G, "The Asian Pacific Association for the Study of the Liver clinical practice guidance : the diagnosis and management of patients with autoimmune hepatitis", Hepatol Int, 15, pp.223~257 (2021)
19. Sook-Hyang Jeong, "Current epidemiology and clinical characteristics of autoimmune liver diseases in South Korea", Clinical and Molecular Hepatology, 24(1), pp.10~19 (2018), 대한간학회
20. European Association for the Study of the Liver, "EASL Clinical Practice Guidelines : Autoimmune hepatitis", J Hepatol, 63, pp.971~1004 (2015)
21. Mack CL, "Diagnosis and management of autoimmune hepatitis in adults and children : 2019 Practice Guidance and Guidelines from the American Association for the Study of Liver Diseases", Hepatology, 72, pp.671~722 (2020)
22. Feld JJ, "Autoimmune hepatitis : effect of symptoms and cirrhosis on natural history and outcome", Hepatology, 42, pp.53~62 (2005)
23. Muratori P, "Autoimmune liver disease and concomitant extrahepatic autoimmune disease", Eur J Gastroenterol Hepatol, 27, pp.1175~1179 (2015)
24. Muratori P, "Features and progression of asymptomatic autoimmune hepatitis in Italy", Clin Gastroenterol Hepatol, 14, pp.139~146 (2016)
25. Stravitz RT, "Autoimmune acute liver failure: proposed clinical and histological criteria", Hepatology, 53, pp.517~526 (2011)
26. Fujiwara K, "Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute-onset autoimmune hepatitis", J Gastroenterol, 43, pp.951~958 (2008)
27. Yasui S, "Clinicopathological features of severe and fulminant forms of autoimmune hepatitis", J Gastroenterol, 46, pp.378~390 (2011)
28. Yasui S, "Importance of computed tomography imaging features for the diagnosis of autoimmune acute liver failure", Hepatol Res, 42, pp.42~50 (2012)
29. Bittermann T, "Sociodemographic and geographic differences in the US epidemiology of autoimmune hepatitis with and without cirrhosis", Hepatology, 77, pp.367~378 (2023)
30. Terziroli Beretta-Piccoli B, "Autoimmmune hepatitis", Cell Mol Immunol, 19, pp.158~176 (2022)
31. Anand L, "Flare of autoimmune hepatitis causing acute on chronic liver failure: Diagnosis and response to corticosteroid therapy", Hepatology, 70, pp.587~596 (2019)
32. Mieli-Vergani G, "Diagnosis and management of pediatric autoimmune liver disease : ESPGHAN hepatology committee position statement", J Pediatr Gastroenterol Nutr, 66, pp.345~360 (2018)
33. Czaja AJ, "The validity and importance of subtypes in autoimmune hepatitis : a point of view", Am J Gastroenterol, 90, pp.1206~1211 (1995)
34. Kim BH, "Clinical features of autoimmune hepatitis and comparison of two diagnostic criteria in Korea : a nationwide, multicenter study", J Gastroenterol Hepatol, 28, pp.128~134 (2013)
35. 정대림, "소아 자가면역성 간염: 임상적 특성, 조직 소견 및 예후", Pediatric Gastroenterology, Hepatology & Nutrition, 7(2), pp.186~196 (2004), 대한소아소화기영양학회
36. Katsumi T, "Epidemiology and surveillance of autoimmune hepatitis in Asia", Liver Int, 42, pp.2015~2022 (2022)
37. Jiménez-Rivera C, "Incidence and characteristics of autoimmune hepatitis", Pediatrics, 136, pp.e1237~e1248 (2015)
38. Lee WS, "Characteristics and outcome of autoimmune liver disease in Asian children", Hepatol Int, 9, pp.292~302 (2015)
39. Homberg JC, "Chronic active hepatitis associated with antiliver", kidney microsome antibody type 1 : a second type of"autoimmune"hepatitis, 1987, pp.7, 1333~1339
40. Muratori P, "Type 1 and type 2 autoimmune hepatitis in adults share the same clinical phenotype", Aliment Pharmacol Ther, 41, pp.1281~1287 (2015)
41. Gregorio GV, "Autoimmune hepatitis in childhood : a 20-year experience", Hepatology, 25, pp.541~547 (1997)
42. Abu Faddan NH, "Clinicolaboratory study on children with auto-immune hepatitis in Upper Egypt", Arab J Gastroenterol, 12, pp.178~183 (2011)
43. Nares-Cisneros J, "Autoimmune hepatitis in children : progression of 20 cases in northern Mexico", Rev Gastroenterol Mex, 79, pp.238~243 (2014)
44. Czaja AJ, "Behavior and significance of autoantibodies in type 1autoimmune hepatitis", J Hepatol, 30, pp.394~401 (1999)
45. Minaga K, "Autoimmune hepatitis and IgG4-related disease", World J Gastroenterol, 25, pp.2308~2314 (2019)
46. Gassert DJ, "Corticosteroidresponsive cryptogenic chronic hepatitis : evidence for seronegative autoimmune hepatitis", Dig Dis Sci, 52, pp.2433~2437 (2007)
47. Wang QX, "Clinical and histological features of autoantibody-negative autoimmune hepatitis in Chinese patients : a single center experience", J Dig Dis, 14, pp.175~180 (2013)
48. Czaja AJ, "Autoantibody-negative autoimmune hepatitis", Dig Dis Sci, 57, pp.610~624 (2012)
49. Boberg KM, "Overlap syndromes : the International Autoimmune Hepatitis Group(IAIHG)position statement on a controversial issue", J Hepatol, 54, pp.374~385 (2011)
50. 박윤상, "Retrospective analysis of autoimmune hepatitis–primary biliary cirrhosis overlap syndrome in Korea: characteristics, treatments, and outcomes", Clinical and Molecular Hepatology, 21(2), pp.150~157 (2015), 대한간학회
51. Trivedi PJ, "Review article : overlap syndromes and autoimmune liver disease", Aliment Pharmacol Ther, 36, pp.517~533 (2012)
52. O’Brien C, "Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis", Hepatology, 48, pp.550~556 (2008)
53. Poupon R, "Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis", Hepatology, 44, pp.85~90 (2006)
54. Czaja AJ, "Diagnosis and management of the overlap syndromes of autoimmune hepatitis", Can J Gastroenterol, 27, pp.417~423 (2013)
55. Abdalian R, "Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis : evaluating the role of routine magnetic resonance imaging", Hepatology, 47, pp.949~957 (2008)
56. Bittencourt PL, "Frequency of concurrent autoimmune disorders in patients with autoimmune hepatitis : effect of age, gender, and genetic background", J Clin Gastroenterol, 42, pp.300~305 (2008)
57. Efe C, "Autoimmune hepatitis", primary biliary cirrhosis overlap syndrome and associated extrahepatic autoimmune diseases, 2012, pp.24, 531~534
58. Wong GW, "Concurrent extrahepatic autoimmunity in autoimmune hepatitis : implications for diagnosis, clinical course and long-term outcomes", Liver Int, 37, pp.449~457 (2017)
59. Sahebjam F, "Autoimmune hepatitis", Front Med, 9, pp.187~219 (2015)
60. Czaja AJ, "Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly", Hepatology, 43, pp.532~538 (2006)
61. Fogel R, "Extrahepatic autoimmune diseases are prevalent in autoimmune hepatitis patients and their first-degree relatives : Survey study", Interact J Med Res, 7, pp.e18~ (2018)
62. Zeng Q, "Relationship between autoimmune liver disease and autoimmune thyroid disease : a cross-sectional study", Scand J Gastroenterol, 55, pp.216~221 (2020)
63. Adiga A, "Lupus hepatitis and autoimmune hepatitis(Lupoid Hepatitis)", Am J Med Sci, 353, pp.329~335 (2017)
64. Kofman S, "Apparent hepatic dysfunction in lupus erythematosus", AMA Arch Intern Med, 95, pp.669~676 (1955)
65. Efe C, "Autoimmune liver disease in patients with systemic lupus erythematosus : a retrospective analysis of 147 cases", Scand J Gastroenterol, 46, pp.732~737 (2011)
66. Runyon BA, "The spectrum of liver disease in systemic lupus erythematosus. Report of 33 histologically-proved cases and review of the literature", Am J Med, 69, pp.187~194 (1980)
67. Lim DH, "Immunoglobulin G levels as a prognostic factor for autoimmune hepatitis combined with systemic lupus erythematosus", Arthritis Care Res(Hoboken), 68, pp.995~1002 (2016)
68. Selmi C, "Rheumatic manifestations in autoimmune liver disease", Rheum Dis Clin North Am, 44, pp.65~87 (2018)
69. Cristansson J, "Corneal changes in a case of hepatitis", Acta Ophthalmol(Copenh), 32, pp.161~164 (1954)
70. Karp JK, "Autoimmune hepatitis in patients with primary Sjögren’s syndrome : a series of twohundred and two patients", Int J Clin Exp Pathol, 3, pp.582~586 (2010)
71. Wong GW, "Association of extrahepatic manifestations with autoimmune hepatitis", Dig Dis, 33(Suppl 2), pp.25~35 (2015)
72. DeFilippis EM, "Clinical presentation and outcomes of autoimmune hepatitis in inflammatory bowel disease", Dig Dis Sci, 60, pp.2873~2880 (2015)
73. Perdigoto R, "Frequency and significance of chronic ulcerative colitis in severe corticosteroidtreated autoimmune hepatitis", J Hepatol, 14, pp.325~331 (1992)
74. Saich R, "Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease", World J Gastroenterol, 14, pp.331~337 (2008)
75. Liberal R, "Autoimmune hepatitis : a comprehensive review", J Autoimmun, 41, pp.126~139 (2013)
76. Cação G, "Concurrent autoimmune hepatitis in multiple sclerosis", Mult Scler, 24, pp.350~353 (2018)
77. de Seze J, "Autoimmune hepatitis and multiple sclerosis : a coincidental association?", Mult Scler, 11, pp.691~693 (2005)
78. 임기영, "자가면역간염의 진단적 접근", 대한내과학회지, 97(1), pp.33~41 (2022), 대한내과학회[DOI]
79. Atsushi Tanaka, "Autoimmune Hepatitis: 2019 Update", Gut and Liver, 14(4), pp.430~438 (2020), 거트앤리버 소화기연관학회협의회[DOI]
80. Zachou K, "Review article : autoimmune hepatitis--current management and challenges", Aliment Pharmacol Ther, 38, pp.887~913 (2013)
81. Hennes EM, "Simplified criteria for the diagnosis of autoimmune hepatitis", Hepatology, 48, pp.169~176 (2008)
82. Laschtowitz A, "Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis", JHEP Rep, 3, pp.100321~ (2021)
83. Joshita S, "Clinical features of autoimmune hepatitis with acute presentation: a Japanese nationwide survey", J Gastroenterol, 53, pp.1079~1088 (2018)
84. Björnsson E, "Patients with typical laboratory features of autoimmune hepatitis rarely need a liver biopsy for diagnosis", Clin Gastroenterol Hepatol, 9, pp.57~63 (2011)
85. Terziroli Beretta-Piccoli B, "Autoimmune hepatitis : Serum autoantibodies in clinical practice", Clin Rev Allergy Immunol, 63, pp.124~137 (2022)
86. Terziroli Beretta-Piccoli B, "The clinical usage and definition of autoantibodies in immunemediated liver disease : A comprehensive overview", J Autoimmun, 95, pp.144~158 (2018)
87. Wies I, "Identification of target antigen for SLA", LP autoantibodies in autoimmune hepatitis, 2000, pp.355, 1510~1515
88. Zachou K, "Autoantibodies and autoantigens in autoimmune hepatitis : important tools in clinical practice and to study pathogenesis of the disease", J Autoimmune Dis, 1, pp.2~ (2004)
89. Targan SR, "High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis", Gastroenterology, 108, pp.1159~1166 (1995)
90. Farias AQ, "Applicability of the IAIHG scoring system to the diagnosis of antimitochondrial", anti-M2 seropositive variant form of autoimmune hepatitis, 2006, pp.21, 887~893
91. Alvarez F, "International Autoimmune hepatitis group report : review of criteria for diagnosis of autoimmune hepatitis", J Hepatol, 31, pp.929~938 (1999)
92. Balitzer D, "Autoimmune hepatitis : review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria", Mod Pathol, 30, pp.773~783 (2017)
93. Lohse AW, "Consensus recommendations for histological criteria of autoimmune hepatitis from the International AIH Pathology Group : Results of a workshop on AIH histology hosted by the European Reference Network on Hepatological Diseases and the European Society of Pathology : Results of a workshop on AIH histology hosted by the European Reference Network on Hepatological Diseases and the European Society of Pathology", Liver Int, 42, pp.1058~1069 (2022)
94. Nguyen Canh H, "Acute presentation of autoimmune hepatitis: a multicentre study with detailed histological evaluation in a large cohort of patients", J Clin Pathol, 70, pp.961~969 (2017)
95. Miyake Y, "Autoimmune hepatitis with acute presentation in Japan", Dig Liver Dis, 42, pp.51~54 (2010)
96. de Boer YS, "Assessment of the histopathological key features in autoimmune hepatitis", Histopathology, 66, pp.351~362 (2015)
97. Guido M, "Liver biopsy sampling in chronic viral hepatitis", Semin Liver Dis, 24, pp.89~97 (2004)
98. Colloredo G, "Impact of liver biopsy size on histological evaluation of chronic viral hepatitis : the smaller the sample, the milder the disease", J Hepatol, 39, pp.239~244 (2003)
99. Palmer T, "Improved tissue sections for medical liver biopsies : a comparison of 16 vs 18 g biopsy needles using digital pathology", J Clin Pathol, 67, pp.415~419 (2014)
100. Johnson PJ, "Meeting report : International autoimmune hepatitis group", Hepatology, 18, pp.998~1005 (1993)
101. Czaja AJ, "Performance parameters of the diagnostic scoring systems for autoimmune hepatitis", Hepatology, 48, pp.1540~1548 (2008)
102. Miyake Y, "Clinical features of autoimmune hepatitis diagnosed based on simplified criteria of the International Autoimmune Hepatitis Group", Dig Liver Dis, 42, pp.210~215 (2010)
103. 이윤나, "한국인 자가면역성 간염을 진단하기 위한 Simplified Scoring Criteria의 가치 및 유용성", 대한내과학회지, 81(3), pp.340~350 (2011), 대한내과학회
104. José Vicente Arcos-Machancoses, "Accuracy of the 2008 Simplified Criteria for the Diagnosis of Autoimmune Hepatitis in Children", Pediatric Gastroenterology, Hepatology & Nutrition, 21(2), pp.118~126 (2018), 대한소아소화기영양학회
105. Kuiper EM, "Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome", Clin Gastroenterol Hepatol, 8, pp.530~534 (2010)
106. Chazouillères O, "Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome : clinical features and response to therapy", Hepatology, 28, pp.296~301 (1998)
107. 김민석, "원발성 담즙성 간경변증으로 진단되고 자가면역성 간염의 Feature를 보이는 한국인 환자에 대한 Simplified Scoring Criteria의 의미", 대한내과학회지, 84(2), pp.211~220 (2013), 대한내과학회[DOI]
108. Czaja AJ, "Cholestatic phenotypes of autoimmune hepatitis", Clin Gastroenterol Hepatol, 12, pp.1430~1438 (2014)
109. Kaya M, "Overlap of autoimmune hepatitis and primary sclerosing cholangitis : an evaluation of a modified scoring system", J Hepatol, 33, pp.537~542 (2000)
110. Björnsson E, "Drug-induced autoimmune hepatitis : clinical characteristics and prognosis", Hepatology, 51, pp.2040~2048 (2010)
111. Castiella A, "Druginduced autoimmune-like hepatitis : a diagnostic challenge", Dig Dis Sci, 56, pp.2501~2502 (2011)
112. Licata A, "Clinical features and outcomes of patients with druginduced autoimmune hepatitis : a retrospective cohort study", Dig Liver Dis, 46, pp.1116~1120 (2014)
113. deLemos AS, "Drug-induced liver injury with autoimmune features", Semin Liver Dis, 34, pp.194~204 (2014)
114. Hisamochi A, "An analysis of drug-induced liver injury, which showed histological findings similar to autoimmune hepatitis", J Gastroenterol, 51, pp.597~607 (2016)
115. Liu ZX, "Immune-mediated drug-induced liver disease", Clin Liver Dis, 6, pp.755~774 (2002)
116. de Boer YS, "Features of autoimmune hepatitis in patients with drug-induced liver injury", Clin Gastroenterol Hepatol, 15, pp.103~112 (2017)
117. Nishida N, "Liver damage related to immune checkpoint inhibitors", Hepatol Int, 13, pp.248~252 (2019)
118. Andrade RJ, "Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period", Gastroenterology, 129, pp.512~521 (2005)
119. Robles-Diaz M, "Use of Hy’s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury", Gastroenterology, 147, pp.109~118 (2014)
120. Czaja AJ, "Drug-induced autoimmune-like hepatitis", Dig Dis Sci, 56, pp.958~976 (2011)
121. Fontana RJ, "Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset", Gastroenterology, 147, pp.96~108 (2014)
122. Ngo Y, "A prospective analysis of the prognostic value of biomarkers(FibroTest)in patients with chronic hepatitis C", Clin Chem, 52, pp.1887~1896 (2006)
123. Poynard T, "Prognostic value of liver fibrosis biomarkers: a metaanalysis", Gastroenterol Hepatol(N Y), 7, pp.445~454 (2011)
124. Poynard T, "Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard", J Hepatol, 56, pp.541~548 (2012)
125. Wai CT, "A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C", Hepatology, 38, pp.518~526 (2003)
126. Sterling RK, "Development of a simple noninvasive index to predict significant fibrosis in patients with HIV", HCV coinfection, 2006, pp.43, 1317~1325
127. Shah AG, "Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 7, pp.1104~1112 (2009)
128. Parkes J, "Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease", Gut, 59, pp.1245~1251 (2010)
129. Parkes J, "Enhanced Liver Fibrosis(ELF)test accurately identifies liver fibrosis in patients with chronic hepatitis C", J Viral Hepat, 18, pp.23~31 (2011)
130. Wu S, "Systematic review : diagnostic accuracy of non-invasive tests for staging liver fibrosis in autoimmune hepatitis", Hepatol Int, 13, pp.91~101 (2019)
131. Shirabe K, "Mac-2 binding protein glycan isomer(M2BPGi)is a new serum biomarker for assessing liver fibrosis : more than a biomarker of liver fibrosis", J Gastroenterol, 53, pp.819~826 (2018)
132. Migita K, "Serum cytokine profiles and Mac-2 binding protein glycosylation isomer(M2BPGi)level in patients with autoimmune hepatitis", Medicine(Baltimore), 97, pp.e13450~ (2018)
133. Mahmud N, "Transient elastography reliably estimates liver fibrosis in autoimmune hepatitis", Clin Exp Hepatol, 5, pp.244~249 (2019)
134. Hartl J, "Timing determines the impact of inflammation and fibrosis", J Hepatol, 65, pp.769~775 (2016)
135. Hartl J, "Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis", J Hepatol, 68, pp.754~763 (2018)
136. Xu Q, "Evaluation of transient elastography in assessing liver fibrosis in patients with autoimmune hepatitis", J Gastroenterol Hepatol, 32, pp.639~644 (2017)
137. Guo L, "Transient Elastography(FibroScan)performs better than non-invasive markers in assessing liver fibrosis and cirrhosis in autoimmune hepatitis patients", Med Sci Monit, 23, pp.5106~5112 (2017)
138. Zeng J, "Non-invasive assessment of liver fibrosis using two-dimensional shear wave elastography in patients with autoimmune liver diseases", World J Gastroenterol, 23, pp.4839~4846 (2017)
139. Li C, "Diagnostic performance of shear wave elastography in patients with autoimmune liver disease", J Ultrasound Med, 38, pp.103~111 (2019)
140. Xing X, "Liver fibrosis with two-dimensional shear-wave elastography in patients with autoimmune hepatitis", Expert Rev Gastroenterol Hepatol, 14, pp.631~638 (2020)
141. Park DW, "Diagnostic performance of a point shear wave elastography(pSWE)for hepatic fibrosis in patients with autoimmune liver disease", PLoS One, 14, pp.e0212771~ (2019)
142. Park CC, "Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease", Gastroenterology, 152, pp.598~607 (2017)
143. Wang J, "Magnetic resonance elastography is accurate in detecting advanced fibrosis in autoimmune hepatitis", World J Gastroenterol, 23, pp.859~868 (2017)
144. Montano Loza AJ, "Current therapy for autoimmune hepatitis", Nat Clin Pract Gastroenterol Hepatol, 4, pp.202~214 (2007)
145. Manns MP, "Diagnosis and management of autoimmune hepatitis", Hepatology, 51, pp.2193~2213 (2010)
146. Montano-Loza AJ, "Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse", Am J Gastroenterol, 102, pp.1005~1012 (2007)
147. Miyake Y, "Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis", Aliment Pharmacol Ther, 24, pp.1197~1205 (2006)
148. Hoeroldt B, "Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center", Gastroenterology, 140, pp.1980~1989 (2011)
149. Dhaliwal HK, "Long-term prognostic significance of persisting histological activity despite biochemical remission in autoimmune hepatitis", Am J Gastroenterol, 110, pp.993~999 (2015)
150. Pape S, "Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group", J Hepatol, 76, pp.841~849 (2022)
151. Muratori L, "Application of the 2010 American Association for the study of liver diseases criteria of remission to a cohort of Italian patients with autoimmune hepatitis", Hepatology, 52, pp.1857~ (2010)
152. Verma S, "Factors predicting relapse and poor outcome in type I autoimmune hepatitis : role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy", Am J Gastroenterol, 99, pp.1510~1516 (2004)
153. Lüth S, "Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis", J Clin Gastroenterol, 42, pp.926~930 (2008)
154. Cook GC, "Controlled prospective trial of corticosteroid therapy in active chronic hepatitis", Q J Med, 40, pp.159~185 (1971)
155. Soloway RD, "Clinical, biochemical, and histological remission of severe chronic active liver disease : a controlled study of treatments and early prognosis", Gastroenterology, 63, pp.820~833 (1972)
156. Murray-Lyon IM, "Controlled trial of prednisone and azathioprine in active chronic hepatitis", Lancet, 1, pp.735~737 (1973)
157. Summerskill WH, "Prednisone for chronic active liver disease : dose titration, standard dose, and combination with azathioprine compared", Gut, 16, pp.876~883 (1975)
158. Tage-Jensen U, "Azathioprine versus prednisone in nonalcoholic chronic liver disease(CLD). Relation to a serological classification", Liver, 2, pp.95~103 (1982)
159. Czaja AJ, "Features and consequences of untreated type 1 autoimmune hepatitis", Liver Int, 29, pp.816~823 (2009)
160. Kogan J, "Prognosis of symptomatic versus asymptomatic autoimmune hepatitis : a study of 68 patients", J Clin Gastroenterol, 35, pp.75~81 (2002)
161. Gordon V, "Treatment and outcome of autoimmune hepatitis(AIH) : Audit of 28 UK centres", Liver Int (2022)[DOI]
162. Schramm C, "Treatment response in patients with autoimmune hepatitis", Hepatology, 52, pp.2247~2248 (2010)
163. Lamers MM, "Treatment options for autoimmune hepatitis : a systematic review of randomized controlled trials", J Hepatol, 53, pp.191~198 (2010)
164. Purnak T, "Treatment response and outcome with two different prednisolone regimens in autoimmune hepatitis", Dig Dis Sci, 62, pp.2900~2907 (2017)
165. Pape S, "Predniso(lo)ne dosage and chance of remission in patients with autoimmune hepatitis", Clin Gastroenterol Hepatol, 17, pp.2068~2075 (2019)
166. Zhang C, "The efficacy and safety of different doses of glucocorticoid for autoimmune hepatitis: A systematic review and meta-analysis", Medicine(Baltimore), 98, pp.e18313~ (2019)
167. Lohse AW, "Autoimmune hepatitis", J Hepatol, 55, pp.171~182 (2011)
168. Relling MV, "Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes : 2018 update", Clin Pharmacol Ther, 105, pp.1095~1105 (2019)
169. Stellon AJ, "Randomised controlled trial of azathioprine withdrawal in autoimmune chronic active hepatitis", Lancet, 1, pp.668~670 (1985)
170. Stellon AJ, "Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal", Hepatology, 8, pp.781~784 (1988)
171. Stern RB, "Controlled trial of synthetic D-penicillamine and prednisone in maintenance therapy for active chronic hepatitis", Gut, 18, pp.19~22 (1977)
172. Johnson PJ, "Azathioprine for longterm maintenance of remission in autoimmune hepatitis", N Engl J Med, 333, pp.958~963 (1995)
173. Heneghan MA, "Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis", J Hepatol, 45, pp.584~591 (2006)
174. Czaja AJ, "Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis", Dig Dis Sci, 51, pp.968~975 (2006)
175. Czaja AJ, "Safety issues in the management of autoimmune hepatitis", Expert Opin Drug Saf, 7, pp.319~333 (2008)
176. Manns MP, "Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis", Gastroenterology, 139, pp.1198~1206 (2010)
177. Czaja AJ, "Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis", Gastroenterology, 119, pp.1312~1316 (2000)
178. Manns MP, "Budesonide in autoimmune hepatitis : The right drug at the right time for the right patient", Clin Gastroenterol Hepatol, 16, pp.186~189 (2018)
179. Peiseler M, "Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis", Clin Gastroenterol Hepatol, 16, pp.260~267 (2018)
180. Geier A, "Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis : influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC", World J Gastroenterol, 9, pp.2681~2685 (2003)
181. Efe C, "Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome", Autoimmun Rev, 11, pp.330~334 (2012)
182. Zachou K, "A real-world study focused on the longterm efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis", Aliment Pharmacol Ther, 43, pp.1035~1047 (2016)
183. Yu ZJ, "Comparison of mycophenolate mofetil with standard treatment for autoimmune hepatitis : a meta-analysis", Eur J Gastroenterol Hepatol, 31, pp.873~877 (2019)
184. Yeoman AD, "Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis", Hepatology, 53, pp.926~934 (2011)
185. Czaja AJ, "Corticosteroids or not in severe acute or fulminant autoimmune hepatitis : therapeutic brinksmanship and the point beyond salvation", Liver Transpl, 13, pp.953~955 (2007)
186. Rahim MN, "Acute severe autoimmune hepatitis : Corticosteroids or liver transplantation?", Liver Transpl, 25, pp.946~959 (2019)
187. Ichai P, "Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis", Liver Transpl, 13, pp.996~1003 (2007)
188. Yeoman AD, "Prognosis of acute severe autoimmune hepatitis(AS-AIH) : the role of corticosteroids in modifying outcome", J Hepatol, 61, pp.876~882 (2014)
189. Zachou K, "Prompt initiation of high-dose i. v. corticosteroids seems to prevent progression to liver failure in patients with original acute severe autoimmune hepatitis", Hepatol Res, 49, pp.96~104 (2019)
190. Karkhanis J, "Steroid use in acute liver failure", Hepatology, 59, pp.612~621 (2014)
191. Czaja AJ, "Acute and acute severe(fulminant)autoimmune hepatitis", Dig Dis Sci, 58, pp.897~914 (2013)
192. Hartl J, "Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis", J Hepatol, 62, pp.642~646 (2015)
193. Guirguis J, "Well-controlled autoimmune hepatitis treatment withdrawal may be safely accomplished without liver-biopsy guidance", Gastroenterol Rep(Oxf), 6, pp.284~290 (2018)
194. Choi J, "Longterm clinical outcomes in patients with autoimmune hepatitis according to treatment response in Asian country", Liver Int, 39, pp.985~994 (2019)
195. Czaja AJ, "Late relapse of type 1 autoimmune hepatitis after corticosteroid withdrawal", Dig Dis Sci, 55, pp.1761~1769 (2010)
196. Czaja AJ, "Clinical features and prognosis of severe chronic active liver disease(CALD)after corticosteroid-induced remission", Gastroenterology, 78, pp.518~523 (1980)
197. Montano-Loza AJ, "Consequences of treatment withdrawal in type 1 autoimmune hepatitis", Liver Int, 27, pp.507~515 (2007)
198. Srivastava S, "Psychological stress is associated with relapse in type 1 autoimmune hepatitis", Liver Int, 30, pp.1439~1447 (2010)
199. van Gerven NM, "Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission", J Hepatol, 58, pp.141~147 (2013)
200. 길재숙, "Long-term Treatment Outcomes for Autoimmune Hepatitis in Korea", Journal of Korean Medical Science, 25(1), pp.54~60 (2010), 대한의학회
201. Czaja AJ, "Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis", Liver Int, 23, pp.116~123 (2003)
202. Hegarty JE, "Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis", Hepatology, 3, pp.685~689 (1983)
203. Czaja AJ, "Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis : a retrospective analysis", Hepatology, 35, pp.890~897 (2002)
204. Czaja AJ, "Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis", Hepatology, 11, pp.1044~1049 (1990)
205. Harrison L, "Stopping immunosuppressive treatment in autoimmune hepatitis(AIH) : Is it justified(and in whom and when)?", Liver Int, 39, pp.610~620 (2019)
206. Seela S, "Autoimmune hepatitis type 1 : safety and efficacy of prolonged medical therapy", Liver Int, 25, pp.734~739 (2005)
207. Buckley L, "Glucocorticoid-Induced Osteoporosis", N Engl J Med, 379, pp.2547~2556 (2018)
208. 박소영, "Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis", 대한골대사학회지, 25(4), pp.195~211 (2018), 대한골대사학회
209. European Association for the Study of the Liver, "EASL Clinical Practice Guidelines on nutrition in chronic liver disease", J Hepatol, 70, pp.172~193 (2019)
210. The Korean Association for the Study of the Liver, "KASL clinical practice guidelines for management of chronic hepatitis B", Clinical and Molecular Hepatology, 28(2), pp.276~331 (2022), 대한간학회
211. Leise MD, "Immunizations in chronic liver disease : what should be done and what is the evidence", Curr Gastroenterol Rep, 15, pp.300~ (2013)
212. "Recommended adult immunization schedule"[URL]
213. Korean Association for the Study of the Liver (KASL), "KASL clinical practice guidelines for management of chronic hepatitis B", Clinical and Molecular Hepatology, 25(2), pp.93~159 (2019), 대한간학회
214. Wörns MA, "Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases", Am J Gastroenterol, 103, pp.138~146 (2008)
215. Pattyn J, "Hepatitis B vaccines", J Infect Dis, 224(12 Suppl 2), pp.S343~S351 (2021)
216. Chang JY, "Thiopurine therapy in patients with inflammatory bowel disease : A focus on metabolism and pharmacogenetics", Dig Dis Sci, 64, pp.2395~2403 (2019)
217. Yang SK, "A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia", Nat Genet, 46, pp.1017~1020 (2014)
218. Katsuyoshi Matsuoka, "NUDT15 gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease", Intestinal research, 18(3), pp.275~281 (2020), 대한장연구학회[DOI]
219. Kim HT, "NUDT15genotype distributions in the Korean population", Pharmacogenet Genomics, 27, pp.197~200 (2017)
220. Miao Q, "Association of genetic variants in TPMT, ITPA, and NUDT15 with azathioprineinduced myelosuppression in southwest china patients with autoimmune hepatitis", Sci Rep, 11, pp.7984~ (2021)
221. Fan X, "NUDT15 polymorphism confer increased susceptibility to thiopurine-induced leukopenia in patients with autoimmune hepatitis and related cirrhosis", Front Pharmacol, 10, pp.346~ (2019)
222. Chang JY, "Genotype-based treatment with thiopurine reduces incidence of myelosuppression in patients with inflammatory bowel diseases", Clin Gastroenterol Hepatol, 18, pp.2010~2018 (2020)
223. Chao K, "Randomised clinical trial : dose optimising strategy by NUDT15genotyping reduces leucopenia during thiopurine treatment of Crohn’s disease", Aliment Pharmacol Ther, 54, pp.1124~1133 (2021)
224. Sutiman N, "Predictive role of NUDT15 variants on thiopurine-induced myelotoxicity in Asian inflammatory bowel disease patients", Pharmacogenomics, 19, pp.31~43 (2018)
225. Kirk AP, "Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis", Gut, 21, pp.78~83 (1980)
226. Narum S, "Corticosteroids and risk of gastrointestinal bleeding : a systematic review and metaanalysis", BMJ Open, 4, pp.e004587~ (2014)
227. "IMURAN Product Information"[URL]
228. Bodelier AG, "Azathioprine induced pneumonitis in a patient with ulcerative colitis", J Crohns Colitis, 3, pp.309~312 (2009)
229. Green CJ, "Re-introduction of azathioprine in previously intolerant patients", Eur J Gastroenterol Hepatol, 18, pp.17~19 (2006)
230. Selvarajah V, "Systematic review : managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs", Aliment Pharmacol Ther, 36, pp.691~707 (2012)
231. Allison AC, "Mechanisms of action of mycophenolate mofetil", Lupus, 14(Suppl 1), pp.s2~s8 (2005)
232. Roberts SK, "Efficacy and safety of mycophenolate mofetil in patients with autoimmune hepatitis and suboptimal outcomes after standard therapy", Clin Gastroenterol Hepatol, 16, pp.268~277 (2018)
233. Santiago P, "Systematic review with meta-analysis : mycophenolate mofetil as a second-line therapy for autoimmune hepatitis", Aliment Pharmacol Ther, 49, pp.830~839 (2019)
234. Abdollahi M, "Tacrolimus and mycophenolate mofetil as second-line treatment in autoimmune hepatitis : Is the evidence of sufficient quality to develop recommendations?", World J Gastroenterol, 26, pp.5896~5910 (2020)
235. Vergani D, "A reasoned approach to the treatment of autoimmune hepatitis", Dig Liver Dis, 53, pp.1381~1393 (2021)
236. Fernandes NF, "Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis", Am J Gastroenterol, 94, pp.241~248 (1999)
237. Than NN, "Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy", Scand J Gastroenterol, 51, pp.329~336 (2016)
238. Scott LJ, "Tacrolimus : a further update of its use in the management of organ transplantation", Drugs, 63, pp.1247~1297 (2003)
239. Brunet M, "Therapeutic drug monitoring of tacrolimuspersonalized therapy : second consensus report", Ther Drug Monit, 41, pp.261~307 (2019)
240. Efe C, "Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis", Clin Gastroenterol Hepatol, 15, pp.1950~1956 (2017)
241. Lohse AW, "Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group", J Hepatol, 73, pp.1496~1506 (2020)
242. Hübener S, "Efficacy of 6-mercaptopurine as second-line treatment for patients with autoimmune hepatitis and azathioprine intolerance", Clin Gastroenterol Hepatol, 14, pp.445~453 (2016)
243. van den Brand FF, "Biochemical efficacy of tioguanine in autoimmune hepatitis : a retrospective review of practice in the Netherlands", Aliment Pharmacol Ther, 48, pp.761~767 (2018)
244. Toksvang LN, "Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia : A systematic review", PLoS One, 14, pp.e0212157~ (2019)
245. de Boer YS, "Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis", Aliment Pharmacol Ther, 37, pp.640~646 (2013)
246. Neuhaus P, "mTOR inhibitors : an overview", Liver Transpl, 7, pp.473~484 (2001)
247. Chatrath H, "Use of sirolimus in the treatment of refractory autoimmune hepatitis", Am J Med, 127, pp.1128~1131 (2014)
248. Ytting H, "Everolimus treatment for patients with autoimmune hepatitis and poor response to standard therapy and drug alternatives in use", Scand J Gastroenterol, 50, pp.1025~1031 (2015)
249. Weiler-Normann C, "Infliximab as a rescue treatment in difficultto-treat autoimmune hepatitis", J Hepatol, 58, pp.529~534 (2013)
250. Ghabril M, "Liver injury from tumor necrosis factor-α antagonists: analysis of thirtyfour cases", Clin Gastroenterol Hepatol, 11, pp.558~564 (2013)
251. Björnsson ES, "Risk of drug-induced liver injury from tumor necrosis factor antagonists", Clin Gastroenterol Hepatol, 13, pp.602~608 (2015)
252. Burak KW, "Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy", Can J Gastroenterol, 27, pp.273~280 (2013)
253. Ramachandran J, "Clinicopathological profile and management of severe autoimmune hepatitis", Trop Gastroenterol, 35, pp.25~31 (2014)
254. Saadah OI, "Long-term outcome of autoimmune hepatitis in children", J Gastroenterol Hepatol, 16, pp.1297~1302 (2001)
255. Ferreira AR, "Effect of treatment of hepatic histopathology in children and adolescents with autoimmune hepatitis", J Pediatr Gastroenterol Nutr, 46, pp.65~70 (2008)
256. Mieli-Vergani G, "Autoimmune hepatitis", J Pediatr Gastroenterol Nutr, 49, pp.158~164 (2009)
257. Vergani D, "Pharmacological management of autoimmune hepatitis", Expert Opin Pharmacother, 12, pp.607~613 (2011)
258. Enweluzo C, "Comparing efficacy between regimens in the initial treatment of autoimmune hepatitis", J Clin Med Res, 5, pp.281~285 (2013)
259. Terziroli Beretta-Piccoli B, "Autoimmune hepatitis : Standard treatment and systematic review of alternative treatments", World J Gastroenterol, 23, pp.6030~6048 (2017)
260. Dumortier J, "Long-term treatment reduction and steroids withdrawal in children with autoimmune hepatitis : a single centre experience on 55 children", Eur J Gastroenterol Hepatol, 21, pp.1413~1418 (2009)
261. Sheiko MA, "Outcomes in pediatric autoimmune hepatitis and significance of azathioprine metabolites", J Pediatr Gastroenterol Nutr, 65, pp.80~85 (2017)
262. Maggiore G, "Treatment of autoimmune chronic active hepatitis in childhood", J Pediatr, 104, pp.839~844 (1984)
263. Maggiore G, "Juvenile autoimmune hepatitis : Spectrum of the disease", World J Hepatol, 6, pp.464~476 (2014)
264. Wehrman A, "Steroid free treatment of autoimmune hepatitis in selected children", J Pediatr, 207, pp.244~247 (2019)
265. Banerjee S, "Azathioprine monotherapy for maintenance of remission in pediatric patients with autoimmune hepatitis", J Pediatr Gastroenterol Nutr, 43, pp.353~356 (2006)
266. El-Koofy NM, "Growth and final height in children with autoimmune hepatitis; A long term observation", Int J Pediatr, 10, pp.15695~15709 (2022)
267. Manwani K, "Long-term growth in children and young people with autoimmune liver disease treated with daily steroids", J Pediatr Gastroenterol Nutr, 75, pp.252~256 (2022)
268. Woynarowski M, "Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents", J Pediatr, 163, pp.1347~1353 (2013)
269. Jaewoan Bae, "Prevention of thiopurine-induced early leukopenia in a Korean pediatric patient with Crohn’s disease who turned out to possess homozygous mutations in NUDT15 R139C", Journal of Yeungnam Medical Science, 37(4), pp.332~336 (2020), 영남대학교 의과대학[DOI]
270. Mohammad S, "Budesonide as first-line therapy for noncirrhotic autoimmune hepatitis in children : a decision analysis", Scand J Gastroenterol, 51, pp.753~762 (2016)
271. Aw MM, "Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children : a 5-year follow-up", J Hepatol, 51, pp.156~160 (2009)
272. Richardson PD, "Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine", J Hepatol, 33, pp.371~375 (2000)
273. Hennes EM, "Mycophenolate mofetil as second line therapy in autoimmune hepatitis?", Am J Gastroenterol, 103, pp.3063~3070 (2008)
274. Zolfino T, "Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin", Gut, 50, pp.713~717 (2002)
275. Baven-Pronk AM, "The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes", Aliment Pharmacol Ther, 34, pp.335~343 (2011)
276. Zizzo AN, "Second-line agents in pediatric patients with autoimmune hepatitis : A systematic review and meta-analysis", J Pediatr Gastroenterol Nutr, 65, pp.6~15 (2017)
277. Alvarez F, "Short-term cyclosporine induces a remission of autoimmune hepatitis in children", J Hepatol, 30, pp.222~227 (1999)
278. Cuarterolo M, "Follow-up of children with autoimmune hepatitis treated with cyclosporine", J Pediatr Gastroenterol Nutr, 43, pp.635~639 (2006)
279. Debray D, "Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis", J Pediatr, 135, pp.111~114 (1999)
280. Malekzadeh R, "Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis", Dig Dis Sci, 46, pp.1321~1327 (2001)
281. Sciveres M, "Effectiveness and safety of ciclosporin as therapy for autoimmune diseases of the liver in children and adolescents", Aliment Pharmacol Ther, 19, pp.209~217 (2004)
282. Cuarterolo ML, "Autoimmune hepatitis in children : prednisone plus azathioprine versus cyclosporine : A randomized trial", J Pediatr Gastroenterol Nutr, 71, pp.376~380 (2020)
283. Marlaka JR, "Tacrolimus without or with the addition of conventional immunosuppressive treatment in juvenile autoimmune hepatitis", Acta Paediatr, 101, pp.993~999 (2012)
284. Efe C, "Tacrolimus and mycophenolate mofetil as second-line therapies for pediatric patients with autoimmune hepatitis", Dig Dis Sci, 63, pp.1348~1354 (2018)
285. D’Agostino D, "Successful treatment of refractory autoimmune hepatitis with rituximab", Pediatrics, 132, pp.e526~e530 (2013)
286. Rajanayagam J, "Infliximab as rescue therapy in paediatric autoimmune hepatitis", J Hepatol, 59, pp.908~909 (2013)
287. Rodrigues S, "Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy : A single center report of 8 cases", World J Gastroenterol, 21, pp.7584~7588 (2015)
288. Mostamand S, "Infliximabassociated immunomediated hepatitis in children with inflammatory bowel disease", J Pediatr Gastroenterol Nutr, 63, pp.94~97 (2016)
289. Kurowski J, "Sirolimus as rescue therapy in pediatric autoimmune hepatitis", J Pediatr Gastroenterol Nutr, 58, pp.e4~e6 (2014)
290. Mieli-Vergani G, "Autoimmune paediatric liver disease", World J Gastroenterol, 14, pp.3360~3367 (2008)
291. van den Brand FF, "Drug withdrawal in patients with autoimmune hepatitis in long-term histological remission : A prospective observational study", Eur J Intern Med, 90, pp.30~36 (2021)
292. Çavuş B, "Is there any predictor for relapse after treatment withdrawal in autoimmune hepatitis patients in the real life?", Int J Immunopathol Pharmacol, 36, pp.3946320221077860~ (2022)
293. Gregorio GV, "Autoimmune hepatitis", sclerosing cholangitis overlap syndrome in childhood : a 16-year prospective study, 2001, pp.33, 544~553
294. Chung YY, "Autoimmune hepatitis in pregnancy : Pearls and pitfalls", Hepatology, 76, pp.502~517 (2022)
295. Graham JJ, "T helper cell immunity in pregnancy and influence on autoimmune disease progression", J Autoimmun, 121, pp.102651~ (2021)
296. Bonney EA, "Alternative theories : Pregnancy and immune tolerance", J Reprod Immunol, 123, pp.65~71 (2017)
297. Bozward AG, "Autoimmune hepatitis : Tolerogenic immunological state during pregnancy and immune escape in post-partum", Front Immunol, 11, pp.591380~ (2020)
298. Braga A, "Autoimmune hepatitis and pregnancy", Best Pract Res Clin Obstet Gynaecol, 68, pp.23~31 (2020)
299. Westbrook RH, "Outcomes of pregnancy in women with autoimmune hepatitis", J Autoimmun, 38, pp.J239~J244 (2012)
300. Terrabuio DR, "Follow-up of pregnant women with autoimmune hepatitis : the disease behavior along with maternal and fetal outcomes", J Clin Gastroenterol, 43, pp.350~356 (2009)
301. Si T, "Systematic review with meta-analysis : outcomes of pregnancy in patients with autoimmune hepatitis", Aliment Pharmacol Ther, 55, pp.1368~1378 (2022)
302. Muratori P, "Spontaneous remission of autoimmune hepatitis during pregnancy", Dig Liver Dis, 34, pp.608~609 (2002)
303. Caballero-Mateos AM, "Autoimmune severe acute fulminant hepatic failure(FHF)during pregnancy", Gastroenterol Hepatol, 41, pp.259~260 (2018)
304. Olsen K, "Type 2 autoimmune hepatitis and nonadherence to medication correlate with premature birth and risk of postpartum flare", Hepatol Commun, 5, pp.1252~1264 (2021)
305. Llovet LP, "Presentation and outcomes of pregnancy in patients with autoimmune hepatitis", Clin Gastroenterol Hepatol, 17, pp.2819~2821 (2019)
306. Grønbaek L, "Pregnancy and birth outcomes in a Danish nationwide cohort of women with autoimmune hepatitis and matched population controls", Aliment Pharmacol Ther, 48, pp.655~663 (2018)
307. Wang CW, "Outcomes of pregnancy in autoimmune hepatitis : A population-based study", Hepatology, 75, pp.5~12 (2022)
308. El Jamaly H, "Systematic review with meta-analysis : autoimmune hepatitis in pregnancy", Scand J Gastroenterol, 56, pp.1194~1204 (2021)
309. Paizis K, "Immunomodulatory drugs in pregnancy and lactation", Aust Prescr, 42, pp.97~101 (2019)
310. Park-Wyllie L, "Birth defects after maternal exposure to corticosteroids : prospective cohort study and meta-analysis of epidemiological studies", Teratology, 62, pp.385~392 (2000)
311. Hviid A, "Corticosteroid use during pregnancy and risk of orofacial clefts", CMAJ, 183, pp.796~804 (2011)
312. Sarkar M, "Reproductive health and liver disease : Practice guidance by the American Association for the Study of Liver Diseases", Hepatology, 73, pp.318~365 (2021)
313. Götestam Skorpen C, "The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation", Ann Rheum Dis, 75, pp.795~810 (2016)
314. Granito A, "Clinical features of type 1 autoimmune hepatitis in elderly Italian patients", Aliment Pharmacol Ther, 21, pp.1273~1277 (2005)
315. Miyake Y, "Clinical features of Japanese elderly patients with type 1autoimmune hepatitis", Intern Med, 46, pp.1945~1949 (2007)
316. Schramm C, "Autoimmune hepatitis in the elderly", Am J Gastroenterol, 96, pp.1587~1591 (2001)
317. Chen J, "Systematic review with metaanalysis : clinical manifestations and management of autoimmune hepatitis in the elderly", Aliment Pharmacol Ther, 39, pp.117~124 (2014)
318. Durazzo M, "Autoimmune hepatitis treatment in the elderly : A systematic review", World J Gastroenterol, 25, pp.2809~2818 (2019)
319. Sonthalia N, "Clinical, serological, histopathological and treatment profile of autoimmune hepatitis in the elderly", Clin Exp Hepatol, 6, pp.13~19 (2020)
320. Kumagai J, "Autoimmune hepatitis following drug-induced liver injury in an elderly patient", Clin J Gastroenterol, 9, pp.156~159 (2016)
321. Rizvi S, "Autoimmune hepatitis in the elderly : Diagnosis and pharmacologic management", Drugs Aging, 35, pp.589~602 (2018)
322. Suzuki A, "The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury", Hepatology, 54, pp.931~939 (2011)
323. Czaja AJ, "Special clinical challenges in autoimmune hepatitis : the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients", Semin Liver Dis, 29, pp.315~330 (2009)
324. Jiang Y, "Characteristics and inpatient outcomes of primary biliary cholangitis and autoimmune hepatitis overlap syndrome", J Clin Transl Hepatol, 9, pp.392~398 (2021)
325. To U, "Overlap syndrome of autoimmune hepatitis and primary biliary cholangitis", Clin Liver Dis, 22, pp.603~611 (2018)
326. Martínez Casas OY, "Autoimmune hepatitis-primary biliary cholangitis overlap syndrome. Long-term outcomes of a retrospective cohort in a university hospital", Gastroenterol Hepatol, 41, pp.544~552 (2018)
327. Al-Chalabi T, "Autoimmune hepatitis overlap syndromes : an evaluation of treatment response, long-term outcome and survival", Aliment Pharmacol Ther, 28, pp.209~220 (2008)
328. Joshi S, "Primary biliary cirrhosis with additional features of autoimmune hepatitis : response to therapy with ursodeoxycholic acid", Hepatology, 35, pp.409~413 (2002)
329. Freedman BL, "Treatment of overlap syndromes in autoimmune liver disease : A systematic review and meta-analysis", J Clin Med, 9, pp.1449~ (2020)
330. Floreani A, "Clinical course and outcome of autoimmune hepatitis", primary sclerosing cholangitis overlap syndrome, 2005, pp.100, 1516~1522
331. Loomba R, "Hepatitis B reactivation associated with immune suppressive and biological modifier therapies : Current concepts, management strategies, and future directions", Gastroenterology, 152, pp.1297~1309 (2017)
332. 정은행, "Regional prevalence of non-alcoholic fatty liver disease in Seoul and Gyeonggi-do, Korea", Clinical and Molecular Hepatology, 19(3), pp.266~272 (2013), 대한간학회[DOI]
333. Takahashi A, "Non-alcoholic fatty liver disease in patients with autoimmune hepatitis", JGH Open, 2, pp.54~58 (2018)
334. De Luca-Johnson J, "Natural history of patients presenting with autoimmune hepatitis and coincident nonalcoholic fatty liver disease", Dig Dis Sci, 61, pp.2710~2720 (2016)
335. Zachou K, "Nonalcoholic fatty liver disease and steatohepatitis in autoimmune hepatitis: Important player or innocent bystander?", J Hepatol, 70, pp.e396~e397 (2019)
336. Adams LA, "The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease", Am J Gastroenterol, 99, pp.1316~1320 (2004)
337. Yatsuji S, "Diagnosing autoimmune hepatitis in nonalcoholic fatty liver disease : is the International Autoimmune Hepatitis Group scoring system useful?", J Gastroenterol, 40, pp.1130~1138 (2005)
338. 강성희, "KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 27(3), pp.363~401 (2021), 대한간학회
339. Dalekos GN, "NAFLD and autoimmune hepatitis : Do not judge a book by its cover", Eur J Intern Med, 75, pp.1~9 (2020)
340. Mendes F, "Recurrent and de novo autoimmune liver diseases", Clin Liver Dis, 15, pp.859~878 (2011)
341. Stirnimann G, "Recurrent and de novo autoimmune hepatitis", Liver Transpl, 25, pp.152~166 (2019)
342. Cho CW, "Comparative analysis of the clinical outcomes of liver transplantation for probable and definite auto-immune hepatitis by international diagnostic scoring criteria", Transplant Proc, 49, pp.1126~1128 (2017)
343. Kwon JH, "De novo autoimmune hepatitis following liver transplantation", Transplant Proc, 50, pp.1451~1456 (2018)
344. Krishnamoorthy TL, "Longterm corticosteroid use after liver transplantation for autoimmune hepatitis is safe and associated with a lower incidence of recurrent disease", Liver Transpl, 22, pp.34~41 (2016)
345. Trouillot TE, "Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis", Liver Transpl Surg, 5, pp.375~380 (1999)
346. Hayashi M, "Allograft rejection after liver transplantation for autoimmune liver diseases", Liver Transpl Surg, 4, pp.208~214 (1998)
347. Vogel A, "Long-term outcome of liver transplantation for autoimmune hepatitis", Clin Transplant, 18, pp.62~69 (2004)
348. Demetris AJ, "Plasma cell hepatitis in liver allografts : Variant of rejection or autoimmune hepatitis?", Liver Transpl, 14, pp.750~755 (2008)
349. Cholongitas E, "Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation : a systematic review", Transpl Int, 27, pp.1039~1049 (2014)
350. Chen K, "Suppression of hepatocellular carcinoma by mycophenolic acid in experimental models and in patients", Transplantation, 103, pp.929~937 (2019)
351. Rigopoulou EI, "Current trends and characteristics of hepatocellular carcinoma in patients with autoimmune liver diseases", Cancers(Basel), 13, pp.1023~ (2021)
352. Reig M, "BCLC strategy for prognosis prediction and treatment recommendation : The 2022 update", J Hepatol, 76, pp.681~693 (2022)
353. Haanen JBAG, "Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 28(suppl_4), pp.iv119~iv142 (2018)
354. Tison A, "Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: A nationwide, multicenter cohort study", Arthritis Rheumatol, 71, pp.2100~2111 (2019)
355. Leonardi GC, "Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders", J Clin Oncol, 36, pp.1905~1912 (2018)
356. Pinter M, "Immunotherapy for advanced hepatocellular carcinoma : a focus on special subgroups", Gut, 70, pp.204~214 (2021)
357. Jensen MD, "Increased cancer risk in autoimmune hepatitis : A Danish nationwide cohort study", Am J Gastroenterol, 117, pp.129~137 (2022)
358. Ngu JH, "Mortality and the risk of malignancy in autoimmune liver diseases : a population-based study in Canterbury, New Zealand", Hepatology, 55, pp.522~529 (2012)
359. Wong RJ, "Development of hepatocellular carcinoma in autoimmune hepatitis patients : a case series", Dig Dis Sci, 56, pp.578~585 (2011)
360. Yeoman AD, "Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis : Implications for follow-up and screening", Hepatology, 48, pp.863~870 (2008)
361. Czaja AJ, "Hepatocellular carcinoma and other malignancies in autoimmune hepatitis", Dig Dis Sci, 58, pp.1459~1476 (2013)
362. Yan LJ, "Sex and regional disparities in incidence of hepatocellular carcinoma in autoimmune hepatitis : a systematic review and meta-analysis", Hepatol Int, 15, pp.1413~1420 (2021)
363. Migita K, "Hepatocellular carcinoma and survival in patients with autoimmune hepatitis (Japanese National Hospital Organization-autoimmune hepatitis prospective study).", Liver Int, 32, pp.837~844 (2012)
364. Dakhoul L, "Older age and disease duration are highly associated with hepatocellular carcinoma in patients with autoimmune hepatitis", Dig Dis Sci, 64, pp.1705~1710 (2019)
365. Hino-Arinaga T, "Risk factors for hepatocellular carcinoma in Japanese patients with autoimmune hepatitis type 1", J Gastroenterol, 47, pp.569~576 (2012)
366. Tansel A, "Incidence and determinants of hepatocellular carcinoma in autoimmune hepatitis : A systematic review and meta-analysis", Clin Gastroenterol Hepatol, 15, pp.1207~1217 (2017)
367. Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC, "2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma", Gut and Liver, 13(3), pp.227~299 (2019), 거트앤리버 소화기연관학회협의회[DOI]
368. Wang KK, "Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis", Hepatology, 10, pp.39~43 (1989)
369. Sharma R, "Cancer risk in patients with autoimmune hepatitis : A nationwide population-based cohort study with histopathology", Am J Epidemiol, 191, pp.298~319 (2022)

관련 논문AI추천